Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Eloxx reported a Q2 net loss of $4.5 million, or $0.66 per share, reflecting the impact of a one-for-eleven reverse stock split executed in May to facilitate uplisting. The company strengthened its balance sheet significantly through a $66.0 million public offering and subsequent uplisting to the Nasdaq Capital Market, ending the quarter with $62.0 million in cash.
Key figures
- Cash
- 62000000
- Net Loss
- 4500000
- Revenue
- 0
- Rd Expenses
- 2840000
- Deal Value Usd
- 66000000
- Offering Price
- 11
- Shares Offered
- 2975000
- Cash runway
- mid-2028
- Reverse split ratio
- 1-for-11
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.